Metformin Use and Development of Esophageal Squamous Cell Carcinoma
In this case-control study, metformin use was associated with substantially lower odds of ESCC. This finding should prompt investigations of metformin as a preventive option in high-risk individuals and as a potential future therapeutic agent for ESCC.
Authors
- Helgi Birgisson (ORCID: https://orcid.org/0000-0002-8246-6159)
- Giola B. Santoni
- Joonas H. Kauppila (ORCID: https://orcid.org/0000-0001-6740-3726)
- Jesper Lagergren (ORCID: https://orcid.org/0000-0002-5143-5448)
- Shao-Hua Xie (ORCID: https://orcid.org/0000-0003-0864-8154)
- Eivind Ness-Jensen
- My Catarina von Euler-Chelpin
Institutions
- University of Copenhagen (DK)
- Karolinska University Hospital (SE)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Oulu University Hospital (FI)
- Levanger Hospital (NO)
- Karolinska Institutet (SE)
- Thomas Foundation (AU)
- Icelandic Cancer Society (IS)
- University of Oulu (FI)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-03-16
- DOI
- https://doi.org/10.1001/jamanetworkopen.2026.2027
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancerfonden
- Vetenskapsrådet